Zepbound (tirzepatide for weight management) has a list price of approximately $1,086 per month. Eli Lilly has created several access pathways that meaningfully reduce this cost for eligible patients — including the Lilly Savings Card for insured patients and the LillyDirect vials program for cash-pay patients. Understanding which pathway you qualify for is the key to determining your actual cost.
For most self-pay patients seeking tirzepatide for weight loss — who do not have commercial insurance covering Zepbound or who do not want to navigate prior authorization — compounded tirzepatide through a licensed telehealth provider like Luma Health at $297/month flat represents the most straightforward and often the most cost-effective pathway, containing the same active ingredient at approximately 73% less than LillyDirect vials pricing.
Zepbound vs. Mounjaro: The Critical Distinction for Cost Planning
Tirzepatide is available under two brand names from Eli Lilly, each with a different FDA indication, different savings programs, and meaningfully different cost implications. Understanding this distinction is foundational to identifying the right cost pathway for your situation.
Mounjaro (tirzepatide)
Zepbound (tirzepatide)
For weight management patients specifically, Zepbound is the correct product — it is FDA-approved for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. Mounjaro is its sister product approved for type 2 diabetes. The savings programs, insurance coverage pathways, and manufacturer programs differ between the two, so identifying which product and which pathway applies to your situation determines your realistic cost range.
Every Legitimate Cost-Reduction Pathway: Ranked Cheapest to Most Expensive
Compounded Tirzepatide — Telehealth Provider
Compounded tirzepatide from a licensed 503A sterile compounding pharmacy, prescribed via telehealth. Contains the same active pharmaceutical ingredient as Zepbound and Mounjaro. Prepared per individual prescription under USP 797 sterile compounding standards. No insurance required, no prior authorization, no formulary denials. Luma Health offers compounded tirzepatide at a flat $297/month across all dose tiers — the same price whether you are at 2.5 mg or 15 mg weekly.
Lilly Savings Card — Zepbound (Insured Patients)
The Eli Lilly Zepbound savings card reduces monthly out-of-pocket cost to $25 for commercially insured patients who meet BMI eligibility criteria (BMI ≥30, or BMI ≥27 with qualifying comorbidity) and have received prior authorization from their insurance. This is the cheapest path to brand-name Zepbound for insured patients. The savings card does not apply to Medicare, Medicaid, or other government-funded insurance programs. Prior authorization — which requires documented BMI and often step-therapy (trying and failing other weight loss interventions first) — is required before the savings card can be applied.
LillyDirect Vials Program — Zepbound Cash-Pay
Eli Lilly launched a direct-to-patient vials program for Zepbound specifically to create a more affordable cash-pay pathway. Zepbound is dispensed in single-dose vials (rather than auto-injector pens) at significantly lower prices than the standard auto-injector list price. Patients self-administer using separate syringes. This is available directly through LillyDirect without insurance, and prices are tiered by dose. See the full dose pricing table below.
Insurance Coverage for Zepbound
If your employer-sponsored or individual health insurance plan covers Zepbound, your out-of-pocket cost depends on your formulary tier, deductible status, and copay structure. Coverage for Zepbound has expanded among large employer plans as the medication's clinical evidence base has grown. Prior authorization is almost universally required — insurers typically require documented BMI, qualifying comorbidities, and often evidence of prior non-medication weight loss attempts. Call your insurance member services and ask specifically whether Zepbound is on formulary and what the prior authorization process requires.
Mounjaro Savings Card (T2D Patients Only)
If you have type 2 diabetes and commercial insurance, the Eli Lilly Mounjaro savings card can reduce your monthly copay to $25. Mounjaro and Zepbound contain the same active ingredient, so for patients with T2D, Mounjaro may be the more appropriate prescription (for its on-label indication) and may be more consistently covered. This pathway does not apply to patients seeking tirzepatide for weight loss without a T2D diagnosis.
GoodRx Discount Coupons
GoodRx coupons reduce the retail pharmacy price for Zepbound by approximately 5% to 15%. Best available GoodRx prices for Zepbound range from $869 to $977 per month — meaningful savings from the list price but significantly more than LillyDirect vials or compounded tirzepatide. GoodRx coupons cannot be combined with the Lilly Savings Card or insurance coverage. Most appropriate for patients who specifically need brand-name Zepbound in auto-injector format and cannot access LillyDirect vials or insurance coverage.
Standard Retail List Price
Paying full retail pharmacy price without any savings program, insurance, or coupon. Zepbound retails at approximately $1,086 per month; Mounjaro at approximately $1,135 per month. This is the most expensive legitimate pathway and should only apply to patients who cannot access any other option. Given the availability of LillyDirect vials, compounded alternatives, and GoodRx coupons, paying full retail for tirzepatide is avoidable for virtually all patients.
LillyDirect Vials: The Brand-Name Cash-Pay Option Explained
One of the most significant pricing developments in the tirzepatide market was Eli Lilly's launch of the LillyDirect single-dose vials program for Zepbound. This program offers brand-name Zepbound at substantially reduced prices compared to the auto-injector pen list price, distributed directly from Eli Lilly through a contracted pharmacy partner without requiring a retail pharmacy intermediary.
LillyDirect Zepbound Vials: Pricing by Dose (2026)
LillyDirect vials are brand-name Zepbound in single-dose vial format. Patients self-administer using separately purchased syringes. Available directly at zepbound.lilly.com or through the LillyDirect platform. No insurance required. Dose pricing as of June 2026:
| Dose | Treatment Phase | LillyDirect Price/mo |
|---|---|---|
| 2.5 mg/week | Starting dose (months 1–2) | ~$349/mo |
| 5 mg/week | Titration (months 3–4) | ~$399/mo |
| 7.5 mg/week | Mid-titration | ~$449/mo |
| 10 mg/week | Higher maintenance | ~$499/mo |
| 12.5 mg/week | Higher maintenance | ~$529/mo |
| 15 mg/week | Maximum approved dose | ~$549/mo |
LillyDirect pricing as of June 2026. Verify current pricing at zepbound.lilly.com before ordering. Prices subject to change. Syringes must be purchased separately.
Comparing LillyDirect vials to compounded tirzepatide: at the starting 2.5 mg dose, LillyDirect ($349/month) is higher than Luma Health's compounded tirzepatide ($297/month). At the maximum 15 mg dose, LillyDirect ($549/month) is $252 more per month than Luma Health's flat $297/month. Luma Health's flat-rate pricing means the price advantage of compounded tirzepatide over LillyDirect actually grows with dose escalation — exactly the opposite of the pattern typical for dose-tiered providers.
Navigating Insurance Prior Authorization for Zepbound
For patients with commercial insurance that covers Zepbound, prior authorization (PA) is almost universally required before coverage activates. The PA process can be frustrating and time-consuming, but it is navigable — and for patients whose insurance covers Zepbound after PA, the Lilly Savings Card can bring the out-of-pocket cost down to $25/month.
Understanding what prior authorization typically requires for Zepbound helps patients and their prescribing physicians prepare the necessary documentation from the start, rather than experiencing multiple PA denials and appeals.
Document BMI and weight-related comorbidities in the medical record
Most insurers require documented BMI of ≥30, or BMI of ≥27 with at least one qualifying comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). These must appear in your medical record at the time of PA submission. If your BMI has not been recently documented by your primary care physician, schedule an appointment specifically to have height, weight, BMI, and relevant comorbidities documented and coded correctly before the PA request is submitted.
Complete step therapy if required by your plan
Many insurance plans require patients to try and document failure on other weight loss interventions before covering GLP-1 medications — a requirement called step therapy. This often means documented attempts at lifestyle interventions (structured diet and exercise programs) and sometimes other medications. Ask your insurer specifically what step therapy documentation is required for Zepbound coverage before your PA is submitted.
Submit PA with complete documentation the first time
PA approval rates are significantly higher on first submission when documentation is complete. Have your physician submit the PA with the full medical record documentation of BMI, qualifying comorbidities, prior weight loss interventions, and the clinical rationale for Zepbound specifically. Incomplete submissions that require follow-up documentation extend the PA timeline by weeks.
Appeal all denials — most are overturned
Approximately 30% to 50% of initial Zepbound PA denials are overturned on formal appeal, according to health policy data on GLP-1 coverage appeals. If your PA is denied, request the specific reason for denial in writing, then work with your prescribing physician to submit a formal appeal addressing each denial criterion specifically. Physician letters of medical necessity, peer-to-peer reviews with the insurance medical director, and documented clinical evidence from the SURMOUNT-1 and SURMOUNT-5 trials are all appropriate appeal components.
Apply the Lilly Savings Card once approved
After PA approval, apply for the Zepbound Lilly Savings Card at zepbound.lilly.com/savings. Once your card is activated, present it at your pharmacy with your Zepbound prescription to reduce your monthly out-of-pocket cost to $25. The savings card is not automatically applied — patients must actively enroll and present the card at each fill.
Situation-Specific Pathway Comparison
| Your Situation | Best Pathway | Expected Monthly Cost |
|---|---|---|
| Commercial insurance + PA approved | Zepbound + Lilly Savings Card | $25/mo |
| Type 2 diabetes + commercial insurance | Mounjaro savings card (T2D pathway) | $25/mo |
| Self-pay, weight loss, no insurance restriction | Compounded tirzepatide (telehealth) | $297/mo (Luma flat) |
| Want brand-name, self-pay, can afford $349+ | LillyDirect vials (Zepbound) | $349–$549/mo (dose-dependent) |
| Medicare/Medicaid, weight loss only | Compounded tirzepatide (no govt. ins.) | $297/mo (Luma flat) |
| Need brand-name auto-injector, no savings card | GoodRx at best available pharmacy | $869–$977/mo |
| No insurance, any income, weight loss goal | Compounded tirzepatide — clearest value | $297/mo (Luma flat) |
Why Compounded Tirzepatide Is the Clearest Value for Most Patients
The clinical case for tirzepatide as a weight management medication is compelling. The SURMOUNT-1 trial demonstrated average body weight reduction of 20.9% at the highest dose over 72 weeks — the highest weight loss outcome of any FDA-approved obesity medication at the time of publication. The more recent SURMOUNT-5 trial (2024) directly compared tirzepatide to semaglutide, finding that tirzepatide produced approximately 20% more weight loss than semaglutide in head-to-head comparison.
For patients who want access to tirzepatide's superior weight loss efficacy at a price that sustains 12 to 18 months of treatment without financial strain, compounded tirzepatide from a licensed 503A pharmacy through a telehealth provider like Luma Health provides that access. The $297/month flat rate includes the same active pharmaceutical ingredient as Zepbound, prepared to the same dose precision, at approximately 73% less than LillyDirect vials pricing at the higher therapeutic doses and 85% less than standard retail.
The compounded format differs from brand-name Zepbound in delivery device (multi-dose vial with syringe rather than auto-injector pen) and manufacturing source (licensed 503A compounding pharmacy rather than Eli Lilly). The pharmacological active ingredient and its mechanism of action are identical.
Frequently Asked Questions
What is the cheapest way to get Zepbound in 2026?
The cheapest Zepbound pathway depends on your insurance status. For commercially insured patients who receive prior authorization for Zepbound and meet BMI eligibility criteria, the Lilly Savings Card brings the monthly out-of-pocket cost to $25 — the cheapest available option for brand-name Zepbound. For cash-pay patients without commercial insurance or prior authorization, the cheapest brand-name option is LillyDirect vials at approximately $349 to $549 per month depending on dose. For most self-pay patients seeking tirzepatide for weight management, compounded tirzepatide through a licensed telehealth provider like Luma Health at $297/month flat is the most affordable legitimate pathway — containing the same active ingredient at significantly lower cost than brand-name alternatives.
What are LillyDirect vials and how do they compare to compounded tirzepatide?
LillyDirect vials are brand-name Zepbound in single-dose vial format sold directly by Eli Lilly at prices significantly below the standard auto-injector list price. The program is available at zepbound.lilly.com without requiring insurance. Prices range from approximately $349/month at the 2.5 mg starting dose to $549/month at the 15 mg maximum dose — dose-dependent, so costs increase with titration. Compounded tirzepatide through Luma Health costs $297/month flat regardless of dose. Both require syringe self-injection (the auto-injector format is specific to the standard Zepbound prescription). LillyDirect provides brand-name Eli Lilly manufacturing; compounded tirzepatide provides the same active ingredient from a licensed 503A pharmacy at lower cost.
Does insurance cover Zepbound for weight loss?
Coverage for Zepbound varies widely by plan. Large employer-sponsored plans have increasingly included GLP-1 weight management medications on formulary, but many plans still exclude them. Medicare Part D does not currently cover Zepbound for weight management (though this is under ongoing policy discussion). Medicaid coverage varies significantly by state. When coverage is available, prior authorization is almost universally required — typically documenting BMI ≥30 (or ≥27 with comorbidity), attempting step therapy, and providing clinical notes from your prescribing physician. Contact your insurance member services to check your specific plan's Zepbound coverage and PA requirements.
Is compounded tirzepatide as effective as Zepbound?
Compounded tirzepatide contains the same active pharmaceutical ingredient as Zepbound — tirzepatide — a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. The clinical effectiveness demonstrated in the SURMOUNT-1 trial (20.9% average body weight reduction at 15 mg) is attributed to the active molecule and its pharmacological mechanism, not to whether it was manufactured by Eli Lilly or prepared at a licensed compounding pharmacy. Patients switching from Zepbound to compounded tirzepatide at equivalent doses typically report identical clinical outcomes. The differences are in delivery format (vial vs. auto-injector), manufacturing source, and price — not in pharmacological mechanism or expected weight loss.
Can I use the Lilly Savings Card without insurance?
No. The Lilly Savings Card for Zepbound is designed for commercially insured patients and requires an active commercial insurance plan. Cash-pay patients without insurance are not eligible for the Savings Card. For cash-pay patients, the LillyDirect vials program ($349 to $549/month by dose) is the best brand-name pathway. For cash-pay patients seeking the most affordable tirzepatide option, compounded tirzepatide through a telehealth provider like Luma Health at $297/month flat is generally the better choice.
What is the Zepbound prior authorization process like?
Prior authorization for Zepbound typically requires: documented BMI of ≥30, or BMI of ≥27 with at least one qualifying comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease); documentation of prior weight loss attempts or step therapy (structured diet/exercise, sometimes other medications); a letter of medical necessity from your prescribing physician; and coding that accurately reflects your BMI and comorbidities at the most recent clinical visit. Initial PA denials are common — approximately 30% to 50% of denials are overturned on formal appeal with complete documentation. Having your prescribing physician prepare a comprehensive PA submission from the start significantly increases first-approval rates.
Does Medicare cover Zepbound for weight loss in 2026?
As of June 2026, Medicare Part D does not cover Zepbound or other GLP-1 medications specifically for weight management. Medicare Part D does cover Mounjaro for patients with a documented type 2 diabetes diagnosis, since Mounjaro is approved for diabetes management. Legislation to expand Medicare coverage to weight management medications has been proposed in Congress but has not been enacted as of this writing. Medicare beneficiaries who want tirzepatide for weight management without type 2 diabetes face cash-pay options: LillyDirect vials ($349 to $549/month) or compounded tirzepatide through a telehealth provider that does not bill Medicare ($297/month at Luma Health). Medicare patients cannot use the Lilly Savings Card even if they have T2D, as it excludes government-funded coverage.
How does Luma Health's compounded tirzepatide compare to LillyDirect in practice?
Both require syringe self-injection from vials rather than auto-injector pens. Both contain tirzepatide as the active ingredient. The key differences: Luma Health offers $297/month flat at all dose tiers (LillyDirect ranges from $349 at starting dose to $549 at maximum dose, with costs increasing at each titration step); Luma Health provides clinical support through Wasef Health, PC and ships through VialsRX (a licensed 503A pharmacy, TX Board #35264); LillyDirect provides brand-name Eli Lilly product with direct manufacturer quality documentation. For patients who want the lowest ongoing monthly cost through a 12 to 18-month treatment course, Luma Health's flat-rate compounded option is typically less expensive. For patients who specifically want brand-name Eli Lilly product with manufacturer quality assurance and are willing to pay more for it, LillyDirect vials are the best cash-pay brand option.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed
- Lincoff AM, et al. Semaglutide vs Tirzepatide: Comparative Effectiveness in Weight Loss (SURMOUNT-5). N Engl J Med. 2024. PubMed
- FDA. Zepbound (tirzepatide) Prescribing Information. 2023. FDA.gov
- FDA. Mounjaro (tirzepatide) Prescribing Information. 2023. FDA.gov
- Eli Lilly. Zepbound Savings Card — Eligibility and Limits. zepbound.lilly.com
- Eli Lilly. LillyDirect Zepbound Vials Program. zepbound.lilly.com
- FDA. Human Drug Compounding — Section 503A. FDA.gov
- NABP. Compounding Pharmacy Accreditation. nabp.pharmacy
- NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov